Moreover, lower expression of CYP3 enzymes, particularly CYP3A4, may influence the survival of ovarian cancer patients as they may be ineffective in metabolizing or activating cyclophosphamide and doxorubicin, the standard drugs used for the treatment of ovarian cancers [113]. This evidence concerns the gene CYP3A4 and ovarian cancer.